超声示胰腺回声增强与血糖进展及新发糖尿病的关联
本回顾性研究纳入2005年1月至2011年12月在三级医院健康体检中接受腹部超声的32346名连续受试者,胰腺回声增强定义为胰腺回声高于肝左叶。随访分析纳入8856人,中位随访3.17年,胰腺回声增强与血糖进展(HR 1.54)及新发糖尿病(HR 1.49)风险升高相关,且独立于HbA1c和NAFLD。
要点
- 胰腺回声增强定义为胰腺回声高于肝左叶,患病率8.4%(2720/32346)。
- 校正混杂因素、HbA1c和NAFLD后,胰腺回声增强与血糖进展风险升高相关(HR 1.54)。
- 胰腺回声增强与新发糖尿病风险升高相关(HR 1.49),独立于HbA1c和NAFLD。
核心结论
- 胰腺回声增强与血糖参数恶化及血糖进展和新发糖尿病风险升高相关,且独立于HbA1c浓度和NAFLD。
研究设计与样本
- 回顾性研究,经机构审查委员会批准并豁免知情同意,纳入2005年1月至2011年12月在三级医院健康体检中接受腹部超声的32346名连续受试者,其中8856人纳入随访分析,中位随访3.17年(四分位距2.01-4.67年)。
关键影像表现/征象
- 胰腺回声增强定义为胰腺回声高于肝左叶。
- 胰腺回声增强患病率为8.4%(2720/32346),NAFLD患病率为41.4%(13389/32346)。
诊断标准与关键数值
- 胰腺回声增强定义为胰腺回声高于肝左叶。
- 血糖进展定义为血糖正常者随访期间新发糖尿病前期或糖尿病,或糖尿病前期者新发糖尿病。
- 随访期间血糖进展1217/8856(13.7%),新发糖尿病449/8856(5.1%)。
- 校正混杂因素、HbA1c和NAFLD后,胰腺回声增强与血糖进展相关(HR 1.54;95%CI 1.23, 1.92;P < .001)。
- 校正混杂因素、HbA1c和NAFLD后,胰腺回声增强与新发糖尿病相关(HR 1.49;95%CI 1.05, 2.11;P = .024)。
临床应用与阅片要点
- 腹部超声发现胰腺回声高于肝左叶时,可提示血糖进展和新发糖尿病风险升高,独立于HbA1c和NAFLD。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the association between increased pancreatic echogenicity (IPE) and the risk of glycemic progression and incident diabetes. Materials and Methods This retrospective study was approved by the institutional review board, with waiver of informed consent. Consecutive individuals who had undergone abdominal ultrasonography as part of a health examination at a tertiary hospital between January 2005 and December 2011 were included. IPE was defined as increased echogenicity of the pancreas compared with that of the left lobe of liver. Glycemic progression was defined as the development of new prediabetes or diabetes in normoglycemic participants or as new diabetes in prediabetic participants during the follow-up period (median, 3.17 years; interquartile range, 2.01-4.67 years). The occurrence of incident diabetes, defined as a new diagnosis of diabetes during follow-up, was also analyzed. Results Mean age of the 32 346 participants was 50.4 years ± 12.2, and 48% (15 489 of 32 346) were female. The prevalence of IPE and nonalcoholic fatty liver disease (NAFLD) was 8.4% (2720 of 32 346) and 41.4% (13 389 of 32 346), respectively. A total of 8856 participants were included in the follow-up analysis. During the 29 819.2 person-years of follow-up, 1217 (13.7%) and 449 (5.1%) of the 8856 participants developed glycemic progression and new diabetes, respectively. IPE was associated with more glycemic progression (hazard ratio, 1.54; 95% confidence interval: 1.23, 1.92; P < .001) and incident diabetes (hazard ratio, 1.49; 95% confidence interval: 1.05, 2.11; P = .024) after adjustment for confounders, HbA1c concentration, and NAFLD. Conclusion Increased pancreatic echogenicity is associated with deteriorating glycemic parameters and higher risk of glycemic progression and incident diabetes, independent of HbA1c concentration and NAFLD. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Hung CS, Tseng PH, Tu CH, et al. Increased Pancreatic Echogenicity with US: Relationship to Glycemic Progression and Incident Diabetes. Radiology. 2018. PMID: 29613841. doi:10.1148/radiol.2018170331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。